Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Plans to Raise $28M Through Private Offering of Equity

NEW YORK, Oct. 18 – Paradigm Genetics of Research Triangle Park said Wednesday it was planning to raise gross proceeds of $28 million through a private offering of its equity to institutional investors.

The company said it hired investment bank JPMorgan H&Q to sell 5.1 million of its shares for $5.50 a share to unnamed institutional investors.

Paradigm said it expected to close the transaction by Oct. 22. The money will be used to help the company to develop its metabolomics platform, to step up its business development efforts, and to boost its working capital reserves. Paradigm said it would also consider using the proceeds to acquire or invest in business and technologies.

The structure of the deal, which is known as a PIPE, or private investment in public equity, is commonly used by publicly traded companies during periods of uncertainty in the capital markets. By offering shares at below-market prices, publicly traded companies hope to drum up demand for their shares that might not exist in the open market.

Paradigm’s shares closed down 57 cents, or 9.3 percent, at $5.55 in trading on the Nasdaq on Wednesday.

Paradigm Genetics is a functional genomics company focused on the areas of human health, nutrition, crop production, and industrial products.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.